Why one drug has six different prices
A GLP-1 doesn’t have a price: it has a set of prices, and which one applies to you depends almost entirely on your insurance status. The same box of Zepbound can cost $25, about $350, about $650, or over $1,000 in the same month, to four different people, at the same pharmacy. The calculator above sorts those routes for your situation and marks the ones you actually qualify for.
Here’s what each route is.
List price is the manufacturer’s sticker. Almost nobody pays it, but every discount is measured from it, so it’s worth knowing.
Your plan’s copay applies only if your plan covers the drug for your indication. This is the cheapest route when it exists, often $25 or less with the savings card stacked on top.
The manufacturer savings card is a commercial-insurance-only program. Federal anti-kickback rules bar these cards for Medicare, Medicaid, and TRICARE, and they generally don’t help the uninsured. Lilly’s Zepbound card has historically had two tiers: a low copay if your plan covers the drug, and a higher capped price if you have commercial insurance that excludes it. Novo’s cards generally require actual coverage.
Self-pay direct from the manufacturer (LillyDirect for Lilly’s drugs, NovoCare Pharmacy for Novo’s) is the route that changed the math for uninsured people. Cash prices run roughly $350 to $500 a month depending on the drug and dose, versus four figures at retail. You don’t need insurance; you just can’t run it through insurance.
Cash at a pharmacy with a discount coupon shaves a modest amount off retail and varies by pharmacy. It’s worth checking, but it rarely beats a manufacturer cash program where one exists.
Compounded via telehealth is the cheapest number on most people’s list and the one that isn’t like the others (see below).
The commercial-insurance fork
If you have an employer or marketplace plan, one fact determines nearly everything: does your plan include anti-obesity medications as a covered benefit?
If yes, you’re in the cheapest scenario available. Expect a prior authorization first (plans routinely require documented BMI, comorbidities, and sometimes prior weight-loss attempts), but once it clears, your copay plus a savings card is usually the lowest number on the board.
If no, the savings card either doesn’t apply or applies at a much higher capped price, and the manufacturer’s self-pay program usually wins. This is the single most common situation for weight-loss GLP-1s, and it’s why the self-pay programs exist at all.
You can find out which you are in one phone call. Ask member services: “Are anti-obesity medications a covered benefit on my plan, and is this drug on the formulary?” If the answer is no, an appeal or formulary exception is often worth trying before you settle into cash pricing, and the insurance checker walks the coverage rules.
Medicare, Medicaid, and the government-plan trap
Government coverage flips the logic in a way that catches people out: you have insurance, and it makes you ineligible for the discounts. Savings cards are off the table entirely.
For type 2 diabetes, that’s usually fine: Part D and state Medicaid programs widely cover the diabetes GLP-1s after a prior authorization, and the Part D out-of-pocket cap limits what a bad year can cost you.
For weight loss, Medicare Part D has historically excluded drugs used only for weight management. Coverage has been opening up where a GLP-1 is prescribed for an approved related condition, such as cardiovascular risk reduction or obstructive sleep apnea, which is a real avenue if you have one of those diagnoses, and worth asking your plan about by name. Medicaid is decided state by state; check your state’s preferred drug list.
Where compounded fits, honestly
Compounded semaglutide and tirzepatide are the cheapest numbers in this tool, often by a wide margin, and they are not the same product as the approved drug. Compounded medications are not FDA-approved or FDA-reviewed for dose, purity, or quality; the reported problems include dosing errors, contamination, and unapproved salt forms. Legal access narrowed sharply once the FDA declared the shortages resolved, and what’s left is limited to narrow, patient-specific circumstances.
We include it because people are spending real money on it and deserve to see it in a price comparison. We never headline it as the cheapest route, we don’t link sellers, and the honest framing is this: it’s a different risk category, not a discount on the same thing. If you use it, use a state-licensed pharmacy and a licensed prescriber, never a site selling “research peptides.”
What this tool can’t know
Every dollar figure here is an estimate of a published price, checked on the date stamped on the tool, and manufacturer programs change quarterly. Your copay is set by your plan and your deductible, not by us. Pharmacy cash prices differ block to block. Nothing here is a quote, and none of it is a substitute for two phone calls: one to the manufacturer’s program, one to your pharmacy. Use the ranking to know which two calls to make.